Tests ethanol-assisted heart ablation for persistent atrial fibrillation
Tests ethanol infusion plus heart ablation in adults with persistent atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Evaluation of PWI Assisted by Marshall Ethanolization in Ablation of Persistent Atrial Fibrillation
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-85 with symptomatic persistent atrial fibrillation not caused by a heart valve problem, who did not respond to at least one rhythm medicine and are planning catheter ablation.
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Symptomatic persistent atrial fibrillation, not caused by a heart valve problem, lasting 1 week or longer.
- Earlier treatment
- Must have tried at least one antiarrhythmic drug without success. Must not have had a previous catheter ablation for atrial fibrillation or heart surgery.
Main reasons for not taking part
- Heart attack, sudden heart failure or new brain infarction within the last 3 months
- Blood clot in the left atrium
- Heart failure NYHA class III-IV or LVEF below 40%
- Obvious liver or kidney problems
- Pregnant, breastfeeding or planning pregnancy, or of childbearing age without reliable contraception
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT06363604, who can take part
Where in China
- Xinhua Hospital, Shanghai Jiao Tong UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Trial code
- NCT06363604
- Record updated
- 12 April 2024
- Original description
This is a prospective, randomized controlled, single-blind, multi-center clinical trial study aiming to investigate whether the strategy of posterior wall isolation (PWI) assisted by vein of Marshall ethanol infusion (VOMEI) could improve the success rate of persistent atrial fibrillation ablation.Read full original descriptionShow less
Randomized Controlled Study of Atrial Posterior Wall Isolation (PWI) Assisted by Vein of Marshall Ethanol Infusion (VOMEI) and Pulmonary Vein Isolation in Persistent Atrial Fibrillation Ablation
This is a prospective, randomized controlled, single-blind, multi-center clinical trial study aiming to investigate whether the strategy of posterior wall isolation (PWI) assisted by vein of Marshall ethanol infusion (VOMEI) could improve the success rate of persistent atrial fibrillation ablation.
Inclusion: Between 18-85 years old; Symptomatic, non-valvular persistent atrial fibrillation (atrial fibrillation duration ≥1 week), and refractory to at least one antiarrhythmic drug; Prepared to undergo atrial fibrillation catheter ablation; Provide informed consent to participate in the study, comply with follow-up trials and evaluation procedures.
Exclusion: With other bleeding disorders that cannot be treated with anticoagulation therapy; Presence of acute conditions such as acute phase after myocardial infarction (within 3 months), acute heart failure or new onset of cerebral infarction within 3 months; On the heart transplant list; With uncontrolled malignant tumor; History of catheter radiofrequency ablation for atrial fibrillation or cardiac surgery; Heart failure with NYHA class III-IV or LVEF<40%; Obvious liver or kidney dysfunction (ALT, AST levels more than 2 times the upper limit of normal, and/or CCr<50%); Women who are pregnant, breastfeeding, planning to become pregnant, or of childbearing age but not using reliable contraception; Life expectancy less than 1 year; With left atrial thrombus.